Hyperuricaemia-Induced Hypertension in Rats by Regulating the RhoA/ROCK Pathway
Kidney and Blood Pressure Research · 2026
DOI: 10.1159/000552806 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney and Blood Pressure Research, 2026. Verfasst von Yan Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, China. Hauptthemen laut MEDLINE: rho-Associated Kinases, Hypertension, Hyperuricemia, rhoA GTP-Binding Protein. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Hyperuricaemia (HUA) is associated with hypertension, but the mechanisms remain unclear. This study investigated whether the RhoA/ROCK pathway mediates HUA-induced vascular remodelling and hypertension.
Methods
Thirty male Sprague-Dawley rats were divided into control, HUA, and fasudil (ROCK inhibitor) groups. Serum uric acid, creatinine, and blood pressure were measured biweekly. Histopathology, qPCR, and Western blotting assessed thoracic aortic changes and RhoA/ROCK pathway activation. Rat vascular smooth muscle cells (VSMCs) were treated with uric acid, with or without RhoA/ROCK inhibitors, to evaluate nitric oxide (NO) levels and protein expression.
Results
HUA significantly increased systolic blood pressure, aortic media thickness, smooth muscle cell proliferation, and expression of RhoA, ROCK 1/2, and MLC1, with elevated phosphorylation of MLC and MYPT-1. Fasudil reduced blood pressure and ameliorated vascular remodelling but did not lower uric acid levels. In VSMCs, HUA decreased NO content, enhanced RhoA membrane translocation, and increased ROCK 2 expression, effects reversed by RhoA or ROCK inhibitors.
Conclusion
HUA promotes hypertension by activating the RhoA/ROCK pathway, leading to vascular remodelling and dysfunction. Inhibition of this pathway attenuates HUA-induced hypertension, highlighting the mechanistic relevance of the RhoA/ROCK pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
- Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang, China.
- Department of Congenial Heart Disease, General Hospital of Northern Theater Command, Shenyang, China.
- Department of Cardiovascular Surgery, General Hospital of Northern Theater Command, Liaoning, China.
- Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, China, zhaoqingchun1967@126.com.
- Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang, China, zhaoqingchun1967@126.com.
Zitieren
APA
Zhang, Y., Wang, Z., Xu, Y., Wang, N., Xu, Z., Ren, T., Zhao, Q., & Meng, W. (2026). Hyperuricaemia-Induced Hypertension in Rats by Regulating the RhoA/ROCK Pathway. Kidney and Blood Pressure Research. https://doi.org/10.1159/000552806
Vancouver
Zhang Y, Wang Z, Xu Y, Wang N, Xu Z, Ren T, et al. Hyperuricaemia-Induced Hypertension in Rats by Regulating the RhoA/ROCK Pathway. Kidney and Blood Pressure Research. 2026. doi:10.1159/000552806
BibTeX
@article{Zhang2026,
author = {Zhang, Yan and Wang, Zhongchao and Xu, Yinli and Wang, Nan and Xu, Zihua and Ren, Tianshu and Zhao, Qingchun and Meng, Weihong},
title = {Hyperuricaemia-Induced Hypertension in Rats by Regulating the RhoA/ROCK Pathway},
journal = {Kidney and Blood Pressure Research},
year = {2026},
doi = {10.1159/000552806}
}
EUVIMED